As FK228 (depsipeptide) is an FDA approved class I HDAC inhibitor used to treat cutaneous T-cell lymphoma [33], studies combining HDAC inhibitors with standard of care treatments for PDAC are warranted and may result in enhanced tumor penetration with reduced toxicity compared to other therapeutic modalities. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.